Cytek BioSciences Inc (NASDAQ:CTKB)’s traded shares stood at 0.4 million during the last session, with the company’s beta value hitting 1.31. At the close of trading, the stock’s price was $5.06, to imply a decrease of -1.56% or -$0.08 in intraday trading. The CTKB share’s 52-week high remains $9.87, putting it -95.06% down since that peak but still an impressive 24.9% since price per share fell to its 52-week low of $3.80. The company has a valuation of $665.44M, with an average of 0.71 million shares in intraday trading volume over the past 10 days and average of 624.20K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Cytek BioSciences Inc (CTKB), translating to a mean rating of 1.67. Of 4 analyst(s) looking at the stock, 0 analyst(s) give CTKB a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 3 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at 0.0.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Cytek BioSciences Inc (NASDAQ:CTKB) trade information
After registering a -1.56% downside in the last session, Cytek BioSciences Inc (CTKB) has traded red over the past five days. The 5-day price performance for the stock is -6.12%, and -6.99% over 30 days. With these gigs, the year-to-date price performance is -44.52%. Short interest in Cytek BioSciences Inc (NASDAQ:CTKB) saw shorts transact 4.08 million shares and set a 6.87 days time to cover.
The extremes give us $8.5 and $8.5 for target low and target high price respectively. As such, CTKB has been trading -67.98% off suggested target high and -67.98% from its likely low.
Cytek BioSciences Inc (CTKB) estimates and forecasts
Looking at statistics comparing Cytek BioSciences Inc share performance against respective industry, we note that the company has underperformed competitors. Cytek BioSciences Inc (CTKB) shares are -22.63% down over the last 6 months, with its year-to-date growth rate lower than industry average at -210.00% against 17.60%. The rating firms project that company’s revenue will grow 5.80% compared to the previous financial year.
Revenue forecast for the current quarter as set by 5 analysts is 51.84M. Meanwhile, for the current quarter, a total of 5 analyst(s) estimate revenue growth to 60.3M.Earnings reports from the last fiscal year show that sales brought in 55.48M and 58.23M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -6.60% before jumping 3.50% in the following quarter.
CTKB Dividends
Cytek BioSciences Inc has its next earnings report out on 2024-Aug-06. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Cytek BioSciences Inc (NASDAQ:CTKB)’s Major holders
Cytek BioSciences Inc insiders hold 8.62% of total outstanding shares, with institutional holders owning 58.65% of the shares at 64.19% float percentage. In total, 58.65% institutions holds shares in the company, led by BLACKROCK INC.. As of 2024-06-30, the company held over 17.07 million shares (or 13.0387% of shares), all amounting to roughly $95.25 million.
The next major institution holding the largest number of shares is VANGUARD GROUP INC with 11.75 million shares, or about 8.972% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $65.54 million.
